The antidepressant clomipramine regulates cortisol intracellular concentrations and glucocorticoid receptor expression in fibroblasts and rat primary neurones

Neuropsychopharmacology

Volumn 28, Issue 9, 2003, Pages 1553-1561

  Pariante, Carmine M ^a   Hye, Abdul ^a   Williamson, Ritchie ^a   Makoff, Andrew ^a   Lovestone, Simon ^a   Kerwin, Robert W ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Antidepressants; Depression; Glucocorticoid receptor; Hypothalamic pituitary adrenal axis; Multidrug resistance p glycoprotein; Multidrug resistance associated protein

Indexed keywords

ANTIDEPRESSANT AGENT; CLOMIPRAMINE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; HYDROCORTISONE; VERAPAMIL; CORTICOSTERONE; TRICYCLIC ANTIDEPRESSANT AGENT; TRITIUM;

ANIMAL CELL; ARTICLE; BRAIN; CELL MEMBRANE TRANSPORT; CONCENTRATION (PARAMETERS); DOWN REGULATION; FIBROBLAST; GENETIC TRANSCRIPTION; MEMBRANE TRANSPORT; NERVE CELL; NERVE CELL CULTURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; WESTERN BLOTTING; ANIMAL; BRAIN CORTEX; CELL CULTURE; COMPARATIVE STUDY; DENSITOMETRY; DOSE RESPONSE; DRUG EFFECT; DRUG INTERACTION; EMBRYO; EXTRACELLULAR SPACE; INSTRUMENTATION; METABOLISM; METHODOLOGY;

ANIMALS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BLOTTING, WESTERN; CELLS, CULTURED; CEREBRAL CORTEX; CLOMIPRAMINE; CORTICOSTERONE; DENSITOMETRY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG INTERACTIONS; EMBRYO; EXTRACELLULAR SPACE; FIBROBLASTS; HYDROCORTISONE; NEURONS; RATS; RECEPTORS, GLUCOCORTICOID; TRITIUM;

EID: 0141446215     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300195     Document Type: Article

References (70)

1. Beck CA, Estes PA, Bona BJ, Muro-Cacho CA, Nordeen SK, Edwards DP (1993). The steroid antagonist RU486 exerts different effects on the glucocorticoid and progesterone receptors. Endocrinology 133: 728-740.
2. Bergman AM, Pinedo HM, Peters GJ (2001). Steroids affect collateral sensitivity to gemcitabine of multidrug-resistant human lung cancer cells. Eur J Pharmacol 416: 19-24.
3. Blom JM, Tascedda F, Carra S, Ferraguti C, Barden N, Brunello N (2002). Altered regulation of CREB by chronic antidepressant administration in the brain of transgenic mice with impaired glucocorticoid receptor function. Neuropsychopharmacology 26: 605-614.
4. Bourgeois S, Gruol DJ, Newby RF, Rajah FM (1993). Expression of an mdr gene is associated with a new form of resistance to dexamethasone-induced apoptosis. Mol Endocrinol 7: 840-851.
5. Bouwer C, Claassen J, Dinan TG, Nemeroff CB (2000). Prednisone augmentation in treatment-resistant depression with fatigue and hypocortisolaemia: a case series. Depress Anxiety 12: 44-50.
6. Brooksbank BW, Brammall MA, Shaw DM (1973). Estimation of cortisol, cortisone and corticosterone in cerebral cortex, hypothalamus and other regions of the human brain after natural death and after death by suicide. Steroids Lipids Res 4: 162-183.
7. Budziszewska B, Jaworska-Feil L, Kajta M, Lason W (2000). Antidepressant drugs inhibit glucocorticoid receptor-mediated gene transcription - a possible mechanism. Br J Pharmacol 130: 1385-1393.
8. Castaing M, Brouant P, Loiseau A, Santelli-Rouvier C, Santelli M, Alibert-Franco S et al (2000). Membrane permeation by multidrug-resistance- modulators and non-modulators: effects of hydrophobicity and electric charge. J Pharm Pharmacol 52: 289-296.
9. Chen J, Rasenick MM (1995). Chronic treatment of C6 glioma cells with antidepressant drugs increases functional coupling between a G protein (Gs) and adenylyl cyclase. J Neurochem 64: 724-732.
10. DeBattista C, Posener JA, Kalehzan BM, Schatzberg AF (2000). Acute antidepressant effects of intravenous hydrocortisone and CRH in depressed patients: a double-blind, placebo-controlled study. Am J Psychiatry 157: 1334-1337.
11. de Kloet ER, Vreugdenhil E, Oitzl MS, Joels M (1998). Brain corticosteroid receptor balance in health and disease. Endocr Rev 19: 269-301.
12. Dinan TG, Lavelle E, Cooney J, Burnett F, Scott L, Dash A et al (1997). Dexamethasone augmentation in treatment-resistant depression. Acta Psychiatr Scand 95: 58-61.
13. Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB et al (2002). Application of three-dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates. Mol Pharmacol 61: 974-981.
14. Felix RA, Barrand MA (2002). P-glycoprotein expression in rat brain endothelial cells: evidence for regulation by transient oxidative stress. J Neurochem 80: 64-72.
15. Ford JM (1996). Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers. Eur J Cancer 32A: 991-1001.
16. Glotzbach RK, Preskorn SH (1982). Brain concentrations of tricyclic antidepressants: single-dose kinetics and relationship to plasma concentrations in chronically dosed rats. Psychopharmacology (Berl) 78: 25-27.
17. Herr AS, Wochnik GM, Rosenhagen MC, Holsboer F, Rein T (2000). Rifampicin is not an activator of glucocorticoid receptor. Mol Pharmacol 57: 732-737.
18. Hery M, Semont A, Fache MP, Faudon M, Hery F (2000). The effects of serotonin on glucocorticoid receptor binding in rat raphe nuclei and hippocampal cells in culture. J Neurochem 74: 406-413.
19. Hirrlinger J, Konig J, Dringen R (2002). Expression of mRNAs of multidrug resistance proteins (Mrps) in cultured rat astrocytes, oligodendrocytes, microglial cells and neurones. J Neurochem 82: 716-719.
20. Holsboer F (2000). The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 23: 477-501.
21. Hrdina PD, Dubas TC (1981). Brain distribution and kinetics of desipramine in the rat. Can J Physiol Pharmacol 59: 163-167.
22. Karssen AM, Meijer OC, van dez Sandt I, de Boer AG, de Lange EC, de Kloet ER (2002). The role of the efflux transporter P-glycoprotein in brain penetration of prednisolone. J Endocrinol 175: 251-260.
23. Karssen AM, Meijer OC, van dez Sandt I, Lucassen PJ, de Lange EC, de Boer AG, de Kloet ER (2001). Multidrug resistance P-glycoprotein hampers the access of cortisol but not of corticosterone to mouse and human brain. Endocrinology 142: 2686-2694.
24. Kralli A, Yamamoto KR (1996). An FK506-sensitive transporter selectively decreases intracellular levels and potency of steroid hormones. J Biol Chem 271: 17152-17156.
25. Kurowski C, Berthold F (1998). Presence of classical multidrug resistance and P-glycoprotein expression in human neuroblastoma cells. Ann Oncol 9: 1009-1014.
26. Kwan P, Sills GJ, Butler E, Gant TW, Meldrum BS, Brodie MJ (2002). Regional expression of multidrug resistance genes in genetically epilepsy-prone rat brain after a single audiogenic seizure. Epilepsia 43: 1318-1323.
27. Lai M, McCormick JA, Chapman KE, Kelly PAT, Seckl JR, Yau JLW (2003). Differential regulation of corticosteroid receptors by monoamine neurotransmitters and antidepressant drugs in primary hippocampal culture. Neuroscience, in press.
28. Lee G, Dallas S, Hong M, Bendayan R (2001). Drug transporters in the central nervous system: brain barriers and brain parenchyma considerations. Pharmacol Rev 53: 569-596.
29. Leslie EM, Deeley RG, Cole SP (2001). Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC1) and related transporters. Toxicology 167: 3-23.
30. Maes M, Song C, Lin AH, Bonaccorso S, Kenis G, De Jongh R et al (1999). Negative immunoregulatory effects of antidepressants: inhibition of interferon-gamma and stimulation of interleukin-10 secretion. Neuropsychopharmacology 20: 370-379.
31. Marsaud V, Mercier-Bodard C, Fortin D, Le Bihan S, Renoir JM (1998). Dexamethasone and triamcinolone acetonide accumulation in mouse fibroblasts is differently modulated by the immunosuppressants cyclosporin A, FK506, rapamycin and their analogues, as well as by other P-glycoprotein ligands. J Steroid Biochem Mol Biol 66: 11-25.
32. Matsuoka Y, Okazaki M, Kitamura Y, Taniguchi T (1999). Developmental expression of P-glycoprotein (multidrug resistance gene product) in the rat brain. J Neurobiol 39: 383-392.
33. McEwen BS, Biron CA, Brunson KW, Bulloch K, Chambers WH, Dhabhar FS et al (1997). The role of adrenocorticoids as modulators of immune function in health and disease: neural, endocrine and immune interactions. Brain Res Brain Res Rev 23: 79-133.
34. Medh RD, Lay RH, Schmidt TJ (1998). Agonist-specific modulation of glucocorticoid receptor-mediated transcription by immunosuppressants. Mol Cell Endocrinol 138: 11-23.
35. Meijer OC, de Lange EC, Breimer DD, de Boer AG, Workel JO, de Kloet ER (1998). Penetration of dexamethasone into brain glucocorticoid targets is enhanced in mdr1A P-glycoprotein knockout mice. Endocrinology 139: 1789-1793.
36. Merry S, Hamilton TG, Flanigan P, Freshney RI, Kaye SB (1991). Circumvention of pleiotropic drug resistance in subcutaneous tumours in vivo with verapamil and clomipramine. Eur J Cancer 27: 31-34.
37. Miller AH, Vogt GJ, Pearce BD (2002). The phosphodiesterase type 4 inhibitor, rolipram, enhances glucocorticoid receptor function. Neuropsychopharmacology 27: 939-948.
38. Mulder HS, Pinedo HM, Timmer AT, Rao BR, Lankelma J (1996). Multidrug resistance-modifying components in human plasma with potential clinical significance. J Exp Ther Oncol 1: 13-22.
39. Nemeroff CB (1996). The corticotropin-releasing factor (CRF) hypothesis of depression: new findings and new directions. Mol Psychiatry 1: 336-342.
40. O'Donnell D, Francis D, Weaver S, Meaney MJ (1995). Effects of adrenalectomy and corticosterone replacement on glucocorticoid receptor levels in rat brain tissue: a comparison between western blotting and receptor binding assays. Brain Res 687: 133-142.
41. Okugawa G, Omori K, Suzukawa J, Fujiseki Y, Kinoshita T, Inagaki C (1999). Long-term treatment with antidepressants increases glucocorticoid receptor binding and gene expression in cultured rat hippocampal neurones. J Neuroendocrinol 11: 887-895.
42. Pariante CM, Makoff A, Lovestone S, Feroli S, Heyden A, Miller AH, Kerwin RW (2001a). Antidepressants enhance glucocorticoid receptor function in vitro by modulating the membrane steroid transporters. Br J Pharmacol 134: 1335-1343.
43. Pariante CM, Miller AH (2001). Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry 49: 391-404.
44. Pariante CM, Papadopoulos AS, Poon L, Checkley SA, English J, Kerwin RW, Lightman S (2002). A novel prednisolone suppression test for the hypothalamic-pituitary-adrenal axis. Biol Psychiatry 51: 922-930.
45. Pariante CM, Pearce BD, Pisell TL, Owens MJ, Miller AH (1997). Steroid-independent translocation of the glucocorticoid receptor by the antidepressant desipramine. Mol Pharmacol 52: 571-581.
46. Pariante CM, Pearce BD, Pisell TL, Sanchez CI, Po C, Su C, Miller AH (1999). The proinflammatory cytokine, interleukin-1alpha, reduces glucocorticoid receptor translocation and function. Endocrinology 140: 4359-4366.
47. Pariante CM, Pearce BD, Pisell TL, Su C, Miller AH (2001b). The steroid receptor antagonists RU40555 and RU486 activate glucocorticoid receptor translocation and are not excreted by the steroid hormones transporter in L929 cells. J Endocrinol 169: 309-320.
48. Pepin MC, Beaulieu S, Barden N (1989). Antidepressants regulate glucocorticoid receptor messenger RNA concentrations in primary neuronal cultures. Brain Res Mol Brain Res 6: 77-83.
49. Pepin MC, Govindan MV, Barden N (1992). Increased glucocorticoid receptor gene promoter activity after antidepressant treatment. Mol Pharmacol 41: 1016-1022.
50. Prima V, Depoix C, Masselot B, Formstecher P, Lefebvre P (2000). Alteration of the glucocorticoid receptor subcellular localization by non steroidal compounds. J Steroid Biochem Mol Biol 72: 1-12.
51. Przegalinski E, Budziszewska B, Siwanowicz J, Jaworska L (1993). The effect of repeated combined treatment with nifedipine and antidepressant drugs or electroconvulsive shock on the hippocampal corticosteroid receptors in rats. Neuropharmacology 32: 1397-1400.
52. Rangarajan PN, Umesono K, Evans RM (1992). Modulation of glucocorticoid receptor function by protein kinase A. Mol Endocrinol 6: 1451-1457.
53. Regina A, Koman A, Piciotti M, El Hafny B, Center MS, Bergmann R et al (1998). Mrp1 multidrug resistance-associated protein and P-glycoprotein expression in rat brain microvessel endothelial cells. J Neurochem 71: 705-715.
54. Reul JM, Stec I, Soder M, Holsboer F (1993). Chronic treatment of rats with the antidepressant amitriptyline attenuates the activity of the hypothalamic-pituitary-adrenocortical system. Endocrinology 133: 312-320.
55. Rossby SP, Nalepa I, Huang M, Perrin C, Burt AM, Schmidt DE et al (1995). Norepinephrine-independent regulation of GRII mRNA in vivo by a tricyclic antidepressant. Brain Res 687: 79-82.
56. Sanchez ER, Hu JL, Zhong S, Shen P, Greene MJ, Housley PR (1994). Potentiation of glucocorticoid receptor-mediated gene expression by heat and chemical shock. Mol Endocrinol 8: 408-421.
57. Schmidt TJ, Meyer AS (1994). Autoregulation of corticosteroid receptors. How, when, where, and why? Receptor 4: 229-257.
58. Shabbits JA, Krishna R, Mayer LD (2001). Molecular and pharmacological strategies to overcome multidrug resistance. Expert Rev Anticancer Ther 1: 585-594.
59. Sisodiya SM, Lin WR, Harding BN, Squier MV, Thom M (2002). Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain 125: 22-31.
60. Steiner AE, Wittliff JL (1985). A whole-cell assay for glucocorticoid binding sites in normal human lymphocytes. Clin Chem 31: 1855-1860.
61. Szabo D, Szabo Jr G, Ocsovszki I, Aszalos A, Molnar J (1999). Anti-psychotic drugs reverse multidrug resistance of tumor cell lines and human AML cells ex-vivo. Cancer Lett 139: 115-119.
62. Ueda K, Okamura N, Hirai M, Tanigawara Y, Saeki T, Kioka N et al (1992). Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem 267: 24248-24252.
63. Uhr M, Holsboer F, Muller MB (2002). Penetration of endogenous steroid hormones corticosterone, cortisol, aldosterone and progesterone into the brain is enhanced in mice deficient for both mdr1a and mdr1b P-glycoproteins. J Neuroendocrinol 14: 753-759.
64. Uhr M, Steckler T, Yassouridis A, Holsboer F (2000). Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption. Neuropsychopharmacology 22: 380-387.
65. Varga A, Nugel H, Baehr R, Marx U, Hever A, Nacsa J et al (1996). Reversal of multidrug resistance by amitriptyline in vitro. Anticancer Res 16: 209-211.
66. Vedder H, Bening-Abu-Shach U, Lanquillon S, Krieg JC (1999). Regulation of glucocorticoid receptor-mRNA in human blood cells by amitriptyline and dexamethasone. J Psychiatr Res 33: 303-308.
67. Williamson R, Scales T, Clark BR, Gibb G, Reynolds CH, Kellie S et al (2002). Rapid tyrosine phosphorylation of neuronal proteins including tau and focal adhesion kinase in response to amyloid-beta peptide exposure: involvement of Src family protein kinases. J Neurosci 22: 10-20.
68. Wolf DC, Horwitz SB (1992). P-glycoprotein transports corticosterone and is photoaffinity-labeled by the steroid. Int J Cancer 52: 141-146.
69. Xia Z, Bergstrand A, DePierre JW, Nassberger L (1999). The antidepressants imipramine, clomipramine, and citalopram induce apoptosis in human acute myeloid leukemia HL-60 cells via caspase-3 activation. J Biochem Mol Toxicol 13: 338-347.
70. Yau JL, Noble J, Hibberd C, Seckl JR (2001). Short-term administration of fluoxetine and venlafaxine decreases corticosteroid receptor mRNA expression in the rat hippocampus. Neurosci Lett 306: 161-164.